Business Wire

Q4 Inc. Transforms Investor Relations with AI-Driven IR Ops Platform

Share

Q4 Inc. (“Q4” or “the company”), the IR Ops platform, addresses the need for a connected approach to workflow and data for investor relations professionals with the AI-driven IR Ops Platform, purpose-built to reduce time spent on admin and enable IROs to be more strategic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606612150/en/

Many Investor Relations Officers (“IROs”) grapple with a fragmented array of IR tools — having to use different software for each function of their role. This disjointed approach results in incomplete and disconnected workflow and data, making investor relations operations costly, slow, and ineffective. Coupled with the fact that many IR teams are mired in administration, IR professionals are challenged to be strategic and help deliver impact to their companies by achieving premium valuations against their peers.

To solve this challenge, Q4 created the IR Ops Platform, a comprehensive solution that integrates all essential IR tools and workflow into a single experience, enabling IR teams to manage their operations more effectively and efficiently. The IR Ops Platform provides clients with easy to use data, workflow, and AI tools that saves tens of hours a month in IR operations. By leveraging the power of this platform, IR professionals can optimize their time and focus on delivering impact instead of tedious admin.

Jake Pisano, VP of Investor Relations at ICR Communications, shared his experience, stating, "The new AI technology on Q4’s IR Ops Platform saves us considerable time when it comes to earnings prep, alleviating stress from the team and providing more flexibility for management review. The AI script generator enables us to seamlessly create initial draft earnings scripts for our clients in as little as 20 minutes. Having access to all of our IR solutions in one ecosystem on the IR Ops Platform has been extremely helpful and further solidifies that Q4 is the go-to platform for all earnings prep."

“With the IR Ops Platform, IR teams can enhance their strategic capabilities, improve investor targeting accuracy, and increase their company’s visibility with the right investors,” remarked Heaps. “By leveraging AI, Q4 is able to streamline administrative tasks, saving IROs valuable time so they can focus on their strategic priorities and delivering impact.”

The company’s IR Ops Platform can be experienced first hand at the upcoming National Investor Relations Institute’s (NIRI) Annual Conference from June 9 - 11, 2024 in San Francisco, California. Opportunities to interact with the new features and functionality of the IR Ops Platform will be available to attendees at the conference, providing an exclusive look at the innovative AI developments at Q4.

About Q4 Inc.

Q4 Inc. is the first IR Ops Platform with the world’s largest set of proprietary investor data, purpose-built to remove obstacles between public companies and their investors. Q4 gives investor relations leaders and their teams the tools to attract, manage, and understand investors — all in one place. The AI-enabled Q4 IR Ops Platform boasts applications for website and event management, engagement analytics, and earnings lifecycle management, including AI Earnings Co-Pilot to generate draft scripts based on historical data, and AI earnings call summaries to understand peer sentiment. The platform also includes a streamlined investor CRM and shareholder intelligence with enhanced metrics to elevate investor targeting strategies. Q4 delivers the data, insights, and workflows that give IR teams the power to focus on what really matters: strategy, relationships, and driving premium valuations for their companies.

The company is a trusted partner to more than 2,600 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.

Q4 is headquartered in Toronto, with offices in New York and London. Learn more at www.q4inc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Heather Noll
Manager, Corporate Communications
media@q4inc.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 17:00:00 CEST | Press release

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm

Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 00:40:00 CEST | Press release

Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing

Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 20:46:00 CEST | Press release

Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s

Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 16:20:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 12:00:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye